Re: Will pharma find ROI in social media?
Its better to be wise than brave. The brave can be separated from the foolish by having a clear assessment of risk and plan to address what happens when (not if) the use of social violates policy. The FDA guideline is clearly too onerous as pre-review of every social interaction is completely impractical, but use of social is inevitable, and the cost of preparedness will be a fraction of cost of response to issues later. The wise are adjusting policies, investing in pre-post review technologies and examining storage/retention capabilities now.